In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelists:
Stephen DiPalma, Chief Financial Officer, Envivo Pharmaceuticals
Ronald S. Eppen, Partner, Foley & Lardner LLP
Mitchell Sanders, CEO and Founder, ECI Biotech
Related Insights
July 8, 2025
Energy Current
What’s the Future for Renewable Energy Tax Credits in Congress?
The One Big Beautiful Bill Act (OBBB) has a significant impact on the renewable energy sector, particularly with changes in the phase-out…
July 8, 2025
Energy Current
Executive Order on PTC and ITC Beginning of Construction
President Trump yesterday issued an executive order, “Ending Market Distorting Subsidies for Unreliable, Foreign Controlled Energy…
July 8, 2025
Foley Viewpoints
The HDHP Telehealth Safe Harbor Returns – For Good This Time
President Trump signed into law the One Big Beautiful Bill Act (the bill) on July 4, 2025. The telehealth safe harbor, which allowed…